Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-2 with Dextrose 1.5% is a peritoneal dialysis solution. Dextrose acts as an osmotic agent to create an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (urea, creatinine) and excess fluid from the blood into the peritoneal cavity, which is then drained out.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
Intraperitoneal: 2-2.5 L per exchange, 4 exchanges per day (continuous ambulatory peritoneal dialysis).
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
Not applicable; dextrose utilization is capacity-limited with half-life of ~1.5 hours in normal circulation. In peritoneal dialysis, the osmotic effect declines over dwell time (2-4 hours) as dextrose is absorbed.
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Dextrose is completely metabolized via glycolysis and the citric acid cycle to carbon dioxide and water; <1% excreted unchanged in urine. Osmotic agent effect terminated by peritoneal absorption and systemic metabolism.
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution